Skip to main content
padlock icon - secure page this page is secure

Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia

Buy Article:

$68.00 + tax (Refund Policy)

Patients vary widely in their responses to drug therapy, often manifested as adverse drug reactions, drug resistance or drug-associated toxicity. Functional polymorphisms in genes encoding enzymes, which are involved in drug action, may underlie these differences thus offering a powerful tool in predicting a treatment outcome.

Several studies have addressed the potential for tailoring individual acute lymphoblastic leukemia (ALL) therapy based on patients' genetics. Several candidate genes have been shown to have a predictive role, among which the best examples are the well-characterized polymorphisms in the thiopurine methyltransferase (TPMT) gene. The impact of TPMT genotypes on 6-MP tolerance, affecting the duration of treatment and the appearance of severe hematotoxicity or secondary malignancies has been well documented. Recent studies suggest that polymorphisms in enzymes of the folate cycle may modify the therapeutic effectiveness and toxicity of antifolates. Polymorphism in the enhancer element located in 5'-UTR of thymidylate synthase gene influenced the outcome of ALL, whereas variants of methylene tetrahydrofolate reductase gene correlated with methotrexate sensitivity. Efforts have been also made to gain a closer insight into the role of polymorphisms in genes that might affect both disease susceptibility and drug metabolism, and some of them (e.g. glutathione S-transferase or quinone oxidoreductase) seem to affect the risk of recurrent disease in children with ALL.

Extending the pharmacogenetics concept to other candidate genes / enzymes and to other drugs might, through comprehensive genetic evaluation, help clinical management of ALL patients.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: acute lymphoblastic; childhood acute lymphoblastic leukemia; pharmacogenetics; quinone oxidoreductase; thiopurine methyltransferase; thymidylate synthase gene

Document Type: Review Article

Publication date: June 1, 2003

More about this publication?
  • Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

    The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more